MedTrace Logo

Pharmacokinetics and Pharmacodynamics Study of Alogliptin in Healthy Korean Participants

NCT01391663 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2013-03-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the Pharmacokinetics and Pharmacodynamics of alogliptin after a single or multiple administrations, once daily (QD), of oral alogliptin in healthy Korean subjects.

Conditions

  • Pharmacokinetics and Pharmacodynamics

Interventions

DRUG

Alogliptin

Alogliptin 12.5 mg, tablets, orally, once daily for up to 7 days.

DRUG

Alogliptin

Alogliptin 25 mg, tablets, orally, once daily for up to 7 days.

DRUG

Alogliptin

Alogliptin 25 mg, tablets, orally, two tablets taken once daily for up to 7 days.

Sponsors & Collaborators

Principal Investigators

  • Clinical Director Clinical Science · Takeda

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01391663 on ClinicalTrials.gov